Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01281150

A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors

Study identifier: NCT01281150
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Metastatic spread (stage IV) or locally advanced and unresectable
    • Patients may have estrogen receptor positive or negative (ER+ or ER-) disease
    • Patients with breast cancer may not be HER2-positive ( 3+), or FISH ratio > 2.2
  • No uncontrolled CNS metastasis

Type of study:

Phase I

Treatment:

  • 1. Dose-escalation phase: 21-day cycles where participants receive veliparib orally twice daily on days 1-5, 8-12, and 15-19, and paclitaxel and carboplatin intravenously on days 3, 10, and 17.
  • 2. Expansion phase: 21-day cycles where participants receive veliparib orally daily on days 1-21, and paclitaxel and carboplatin intravenously on days 3 and 10.

Study site:

Pennsylvania
Hershey
Penn State Hershey Cancer Institute at Milton S. Hershey Medical Center
Contact: Chandra P. Belani 717-531-1078 cbelani@psu.edu

Pittsburgh
UPMC Cancer Center at Magee-Womens Hospital
Contact: Edward Chu 412-623-5898 chue2@upmc.edu


Page updated 06/20/13